Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach.
10.1007/s11684-021-0880-3
- Author:
Liang DAI
1
;
Jingjuan XU
1
;
Baocheng LIU
2
;
Yanqi DANG
1
;
Ruirui WANG
2
;
Lijie ZHUANG
3
;
Dong LI
4
;
Lulu JIAO
5
;
Jianying WANG
2
;
Lei ZHANG
2
;
Linda L D ZHONG
1
;
Wenjun ZHOU
1
;
Guang JI
6
Author Information
1. Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
2. Shanghai Innovation Centre of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
3. Sanlin Health Centre of Pudong New District, Shanghai, 200120, China.
4. Zhangjiang Health Centre of Pudong New District, Shanghai, 201203, China.
5. Beicai Health Centre of Pudong New District, Shanghai, 201204, China.
6. Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. jiliver@vip.sina.com.
- Publication Type:Journal Article
- Keywords:
Chinese herbal medicine;
DNA N6-methyladenine modification;
insulin resistance;
non-alcoholic fatty liver disease;
randomized controlled trial
- MeSH:
Humans;
Non-alcoholic Fatty Liver Disease/drug therapy*;
Overweight/drug therapy*;
Insulin Resistance;
Obesity/drug therapy*;
China;
DNA/therapeutic use*
- From:
Frontiers of Medicine
2022;16(5):745-759
- CountryChina
- Language:English
-
Abstract:
Lingguizhugan Decoction (LGZG) has been investigated in basic studies, with satisfactory effects on insulin resistance in non-alcoholic fatty liver disease (NAFLD). This translational approach aimed to explore the effect and underlying mechanism of LGZG in clinical setting. A randomized, double-blinded, placebo-controlled trial was performed. A total of 243 eligible participants with NAFLD were equally allocated to receive LGZG (two groups: standard dose and low dose) or placebo for 12 weeks on the basis of lifestyle modifications. The primary efficacy variable was homeostasis model assessment of insulin resistance (HOMA-IR). Analyses were performed in two populations in accordance with body mass index (BMI; overweight/obese, BMI ⩾ 24 kg/m2; lean, BMI < 24 kg/m2). For overweight/obese participants, low-dose LGZG significantly decreased their HOMA-IR level compared with placebo (-0.19 (1.47) versus 0.08 (1.99), P = 0.038). For lean subjects, neither dose of LGZG showed a superior effect compared with placebo. Methylated DNA immunoprecipitation sequencing and real-time qPCR found that the DNA N6-methyladenine modification levels of protein phosphatase 1 regulatory subunit 3A (PPP1R3A) and autophagy related 3 (ATG3) significantly increased after LGZG intervention in overweight/obese population. Low-dose LGZG effectively improved insulin resistance in overweight/obese subjects with NAFLD. The underlying mechanism may be related to the regulation of DNA N6-methyladenine modification of PPP1R3A and ATG3. Lean subjects may not be a targeted population for LGZG.
